Results 111 to 120 of about 169 (166)

Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) recently celebrated its 20th anniversary, reflecting two decades of major contributions to Alzheimer's research through open data sharing and longitudinal multimodal assessments. This review synthesizes 122 high‐impact studies using ADNI data or biospecimens from 2023 to mid‐2025 to ...
Dallas P. Veitch, Melanie J. Miller, Shaveta Kanoria, Paul S. Aisen, Laurel A. Beckett, Robert C. Green, Danielle J. Harvey, Clifford R. Jack Jr., William Jagust, Edward B. Lee, Kwangsik Nho, Rachel Nosheny, Ozioma C. Okonkwo, Richard J. Perrin, Ronald C. Petersen, Monica Rivera Mindt, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga, Duygu Tosun, Susan M Landau, Michael W. Weiner, for the Alzheimer's Disease Neuroimaging Initiative   +22 more
wiley   +1 more source

Remote, self‐administered, smartphone cognitive testing in a registry‐based cohort: Feasibility, reliability, and validity findings

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract BACKGROUND Remote, smartphone‐based cognitive testing may improve access to cognitive assessments for Alzheimer's disease and related dementias. We evaluated the feasibility, reliability, and validity of unsupervised smartphone‐based cognitive tests in a registry‐based cohort.
Sreya Dhanam, Mark Sanderson‐Cimino, Jack Carson Taylor, Emily W. Paolillo, Ray Fregly, Winnie Kwang, Paul Maruff, Amy Wise, Hilary W. Heuer, Leah K. Forsberg, Joel H. Kramer, Bradley F. Boeve, Howard J. Rosen, R. Scott Mackin, Michael W. Weiner, Rachel L. Nosheny, Adam L. Boxer, Adam M. Staffaroni, and the Brain Health Registry   +18 more
wiley   +1 more source

Sleep and dementia: Assessing established dementia‐related factors using multivariable Mendelian randomization

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION The relationship between sleep, other dementia risk factors, and dementia remains unclear. We aim to explore these associations using a two‐sample Mendelian randomization (MR) approach. METHODS We identified genetic instrumental variables for sleep characteristics from the UK Biobank and obtained summary‐level genetic association ...
Yunyun Guo, Rui Wang, Shireen Sindi, Lefkos T Middleton, Miia Kivipelto   +4 more
wiley   +1 more source

Hippocampal GFAP in aging: Associations with AD and LATE‐NC pathologies and cognitive decline in older adults

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Plasma glial fibrillary acidic protein (GFAP) is an emerging biomarker for Alzheimer's disease (AD) progression in clinical studies, yet the role of brain GFAP in AD/AD‐related dementias (ADRD) pathologies and cognitive decline remains unclear. METHODS GFAP burden from CA1‐subiculum of the hippocampus were quantified.
Sonal Agrawal, Lei Yu, Sue E. Leurgans, Jialiang Li, Alifiya Kapasi, Puja Agarwal, Jeffrey L. Dage, Lisa L. Barnes, David A. Bennett, Patricia Boyle, Julie A. Schneider   +10 more
wiley   +1 more source

Blood biomarker of Lewy body disease

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Lewy Body Disease

Southern Medical Journal, 1996
Lewy bodies have historically been considered a histopathologic hallmark of idiopathic Parkinson's disease. Recently, it has become clear that Lewy bodies play a role in neurodegenerative processes other than idiopathic Parkinson's disease, including diffuse Lewy body disease and diffuse Lewy bodies with concomitant Alzheimer's disease changes.
T A, Smith, R A, Prayson
openaire   +2 more sources

Fulminant Lewy body disease

Movement Disorders, 2006
AbstractThe clinical distinction between Parkinson's disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB) is challenged by most neuropathological studies showing nearly identical changes in both conditions. We report an unusual case of PD evolving into a rapidly progressive dementia leading to death within 3 months that showed nearly ...
Momjian-Mayor, Isabelle, Pizzolato, Gianpaolo, Burkhardt, Karim, Landis, Theodor, Coeytaux, Alessandra Cécile Maria, Burkhard, Pierre   +5 more
openaire   +2 more sources

Familial Lewy Body Diseases

Journal of Geriatric Psychiatry and Neurology, 2002
Lewy body disease includes clinically and pathologically defined disorders in which Lewy bodies occur in the nervous system. In recent years, the molecular features of these disorders have been emerging. Several genetic loci have been identified in association with familial Lewy body disease; however, the genetic risks underlying most cases of familial
Katrina, Gwinn-Hardy, Amanda Adam, Singleton   +1 more
openaire   +2 more sources

Aneuploidy in Lewy body diseases

Neurobiology of Aging, 2015
An increase in DNA content is associated with neuronal degeneration in Alzheimer's disease but has not been evaluated in Lewy body diseases. Using stereological principles, flow cytometry, and standard histopathologic methods, we evaluated the number and DNA content of neurons and all cells and the severity of Lewy and Alzheimer pathologies, in brain ...
Yue Yang, Claire Shepherd, Glenda Halliday   +2 more
openaire   +2 more sources

Lrrk2 and Lewy body disease

Annals of Neurology, 2006
AbstractObjectiveThe Lrrk2 kinase domain G2019S substitution is the most common genetic basis of familial and sporadic parkinsonism. Patients harboring the G2019S substitution usually present with clinical Parkinson's disease.MethodsHerein, we report that the most common neuropathology of G2019S‐associated Parkinson's disease is Lewy body disease ...
Owen A, Ross, Mathias, Toft, Andrew J, Whittle, Joseph L, Johnson, Spiridon, Papapetropoulos, Deborah C, Mash, Irene, Litvan, Mark F, Gordon, Zbigniew K, Wszolek, Matthew J, Farrer, Dennis W, Dickson   +10 more
openaire   +2 more sources